All Compounds

Semaglutide 3mg

Semaglutide

GLP-1 receptor agonist. 99.1% purity. Starter 3mg vial suited to initial dose-titration research; STEP-1 trial recorded −14.9% mean body weight at 68 weeks.

Semaglutide 6mg

Semaglutide

GLP-1 receptor agonist. 99.1% purity. Mid-range 6mg vial supports two-vial titration schedules; STEP-1 Phase 3 mean weight reduction −14.9% over 68 weeks.

Semaglutide 12mg

Semaglutide

GLP-1 receptor agonist. 99.0% purity. 12mg vial accommodates multi-week maintenance dosing research; STEP-1 trial: −14.9% body weight, reduced CVD markers.

Semaglutide 20mg

Semaglutide

GLP-1 receptor agonist. 99.0% purity. 20mg vial provides extended-protocol supply; STEP-1 data: −14.9% body weight, improved glycaemic indices at 68 weeks.

Semaglutide 30mg

Semaglutide

GLP-1 receptor agonist. 99.0% purity. 30mg bulk research vial; STEP-1 Phase 3 −14.9% body weight; enables longitudinal titration studies without mid-study reorder.

Tirzepatide 15mg

Tirzepatide

Dual GLP-1/GIP receptor agonist. 99.2% purity. 15mg vial; SURMOUNT-1 Phase 3: −20.9% body weight at 72 weeks, greater efficacy than mono-agonist controls.

Tirzepatide 30mg

Tirzepatide

Dual GLP-1/GIP receptor agonist. 99.2% purity. 30mg two-dose supply; SURMOUNT-1 −20.9% at 72 weeks; supports back-to-back protocol cycles without interruption.

Tirzepatide 60mg

Tirzepatide

Dual GLP-1/GIP receptor agonist. 99.2% purity. 60mg bulk research vial; SURMOUNT-1 Phase 3 −20.9% body weight; designed for extended comparative or multi-subject studies.

Retatrutide 10mg

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist. 98.9% purity. Starter 10mg vial; Phase 2 trial: −28.7% body weight at 48 weeks — highest recorded reduction in Phase 2 obesity data.

Retatrutide 15mg

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist. 98.9% purity. 15mg mid-supply vial; Phase 2: −28.7% at 48 weeks; glucagon co-agonism drives additional energy expenditure vs dual agonists.

Retatrutide 20mg

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist. 98.9% purity. 20mg vial for maintenance-phase protocols; Phase 2 −28.7% at 48 weeks with dose-dependent adipose loss curve.

Retatrutide 30mg

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist. 98.9% purity. 30mg bulk vial; Phase 2 −28.7% at 48 weeks; sufficient supply for full 12-week research cycle at 2.5mg weekly.

Cagrilintide 5mg

Cagrilintide

Long-acting amylin analogue targeting area postrema and NTS satiety receptors. 98.8% purity. 5mg starter vial; slows gastric emptying and reduces caloric intake in preclinical models.

Cagrilintide 10mg

Cagrilintide

Long-acting amylin analogue. 98.8% purity. 10mg extended-supply vial; central satiety pathway activation distinct from GLP-1 mechanism, enabling complementary co-administration research.

Mazdutide 6mg

Mazdutide

GLP-1/GcgR dual receptor agonist. 98.5% purity. Phase 2 data in T2D shows weight reduction and improved lipid profiles; 6mg single vial for initial mechanistic metabolic research.

Survodutide 10mg

Survodutide

GLP-1/GcgR dual agonist. 98.5% purity. 10mg vial; Phase 2 NASH and obesity trial data demonstrate hepatic fat reduction alongside adipose loss via glucagon receptor co-activation.

Cagri-Sema Blend 10mg

Pre-formulated Cagrilintide 5mg + Semaglutide 10mg blend. 98.7% purity. CagriSema Phase 2: −15.6% weight loss at 32 weeks; dual amylin + GLP-1 pathway co-activation in single vial.

Cagri-Reta 5mg

Cagrilintide + Retatrutide research blend, 5mg total. 98.5% purity. Combines amylin analogue satiety signalling with triple GLP-1/GIP/glucagon agonism; starter-scale co-agonist protocol vial.

Cagri-Reta 10mg

Cagrilintide + Retatrutide research blend, 10mg total. 98.5% purity. Amylin + triple-receptor agonism co-administration supply; supports two-week extended-dose comparative studies.

Reta-Cagri 5mg/5mg

Retatrutide 5mg + Cagrilintide 5mg equimolar pre-formulated stack. 98.5% purity. Triple GLP co-agonism plus central amylin satiety — distinct dual-pathway mechanistic research format.

AOD9604 2mg

AOD9604

GH fragment 176-191. 99.0% purity. Starter 2mg vial; stimulates lipolysis via β3-adrenergic receptor pathway without elevating IGF-1 levels or altering glucose metabolism.

AOD9604 5mg

AOD9604

GH fragment 176-191. 99.0% purity. 5mg titration-range vial; selective lipolytic activity decoupled from somatogenic effects; suitable for dose-response lipolysis studies.

AOD9604 10mg

AOD9604

GH fragment 176-191. 99.0% purity. 10mg extended-supply vial; β3-adrenergic lipolysis stimulation without IGF-1 or insulin axis interference; supports multi-week protocols.

Adipotide (FTPP) 5mg

Adipotide (FTPP)

Proapoptotic peptidomimetic targeting prohibitin on adipose vasculature. 98.7% purity. 5mg vial; preclinical NHP data show selective visceral white adipose tissue reduction via vascular apoptosis.

Adipotide (FTPP) 10mg

Adipotide (FTPP)

Proapoptotic peptidomimetic targeting adipose vascular prohibitin. 98.7% purity. 10mg dual-study supply; NHP preclinical data indicate dose-dependent visceral fat reduction without systemic toxicity.

Tesofensine 500mcg x30 Capsules

Tesofensine

Triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline). 99.0% purity. 500mcg capsules, 30-count; Phase 2 data: −12.8 kg at 24 weeks, distinct CNS-mediated satiety mechanism.

Tesofensine 500mcg x30 Tablets

Tesofensine

Triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline). 99.0% purity. 500mcg tablet format, 30-count; same Phase 2 efficacy profile as capsule form, alternate oral delivery.

O-304 (ATX-304) 100mg x60 Capsules

O-304 (ATX-304)

Pan-AMPK activator. 98.8% purity. 100mg capsules, 60-count (60-day supply); Phase 2 data in T2D and NASH; activates all AMPK complexes without AMP mimicry.

SLU-PP-332 100mg x120 Capsules

SLU-PP-332

ERRα/γ nuclear receptor agonist. 98.6% purity. 100mg capsules, 120-count bulk supply; upregulates oxidative phosphorylation gene networks mimicking endurance-exercise metabolic adaptations.

SLU-PP-332 100mg x30 Capsules

SLU-PP-332

ERRα/γ nuclear receptor agonist. 98.6% purity. 100mg capsules, 30-count starter supply; activates mitochondrial biogenesis and fatty acid oxidation pathways in skeletal muscle.

SLU-PP-332 1mg/mL 30mL

SLU-PP-332

ERRα/γ agonist, liquid format 1mg/mL × 30mL. 98.6% purity. Low-concentration solution for precise micro-dose titration research; exercise-mimetic transcriptional activation.

SLU-PP-332 1mg x30 Capsules

SLU-PP-332

ERRα/γ agonist, 1mg oral capsules × 30. 98.6% purity. Entry-level dose format; ERRα/γ co-activation drives mitochondrial biogenesis without direct AMPK engagement.

SLU-PP-332 5mg/mL 30mL

SLU-PP-332

ERRα/γ agonist, liquid 5mg/mL × 30mL. 98.6% purity. Higher-concentration solution providing 150mg total; suitable for escalating-dose ERR agonism research protocols.

AICAR 50mg

AICAR (Acadesine)

AMPK activator (acadesine). 99.1% purity. 50mg vial; mimics AMP elevation to activate AMPK, improving insulin sensitivity and inducing mitochondrial biogenesis in skeletal muscle models.

BAM-15 30mg/mL 30mL

BAM-15

Mitochondrial protonophore uncoupler. 98.5% purity. 30mg/mL × 30mL liquid; increases mitochondrial energy expenditure by dissipating proton gradient without reducing membrane potential.

BAM-15 50mg/mL 30mL

BAM-15

Mitochondrial protonophore uncoupler. 98.5% purity. High-concentration 50mg/mL × 30mL; same proton gradient dissipation mechanism; fewer injections per session vs 30mg/mL format.

L-Carnitine 400mg/mL

L-Carnitine

L-Carnitine injectable solution, 400mg/mL. 99.5% purity. Facilitates long-chain fatty acid transport across inner mitochondrial membrane via CPT-1; standard concentration research format.

L-Carnitine 5-Pack 600mg

L-Carnitine

L-Carnitine 600mg/mL, 5-vial research pack. 99.5% purity. Multi-vial supply for longitudinal beta-oxidation studies; CPT-1 mediated mitochondrial fatty acid transport mechanism.

L-Carnitine 600mg/mL

L-Carnitine

L-Carnitine injectable, high-concentration 600mg/mL single vial. 99.5% purity. Reduced injection volume vs 400mg/mL format; same CPT-1 fatty acid transport mechanism.

Sermorelin 2mg

Sermorelin

Synthetic GHRH(1-29) analogue. 99.0% purity. 2mg starter vial; binds pituitary GHRH receptor to stimulate endogenous GH secretion; shortest supply for initial pulse-pattern research.

Sermorelin 5mg

Sermorelin

Synthetic GHRH(1-29) analogue. 99.0% purity. 5mg mid-range vial; pituitary GH secretion via GHRH-R activation; suitable for multi-week dose-frequency studies.

Sermorelin 10mg

Sermorelin

Synthetic GHRH(1-29) analogue. 99.0% purity. 10mg extended-supply vial; supports ~30 daily injections at standard 300mcg research dose without mid-protocol reorder.

Ipamorelin 10mg

Ipamorelin

Selective GH secretagogue (pentapeptide). 99.2% purity. 10mg vial; ghrelin receptor agonist triggering discrete GH pulses without co-elevating cortisol, prolactin, or ACTH.

CJC-1295 No DAC 5mg

CJC-1295 (No DAC)

GHRH analogue, no Drug Affinity Complex. 99.1% purity. 5mg starter vial; ~30-minute active window preserves natural ultradian GH pulse architecture — distinct from DAC variant.

CJC-1295 No DAC 10mg

CJC-1295 (No DAC)

GHRH analogue, no Drug Affinity Complex. 99.1% purity. 10mg extended-supply vial; short half-life mimics physiological GHRH pulsatility; supports 30+ injection-cycle research.

CJC-1295 with DAC 10mg

CJC-1295 (DAC)

GHRH analogue with Drug Affinity Complex. 99.0% purity. 10mg vial; DAC conjugation extends half-life to ~6–8 days via albumin binding, enabling once-weekly GH elevation protocols.

GHRP-2 10mg

GHRP-2 (Pralmorelin)

GHRP-2 (Pralmorelin), ghrelin receptor agonist. 99.0% purity. 10mg vial; generates strong GH secretagogue pulse; co-elevation of cortisol and prolactin noted — differentiated from ipamorelin profile.

GHRP-6 10mg

GHRP-6

Hexapeptide ghrelin receptor agonist. 99.0% purity. 10mg vial; robust GH secretagogue with concurrent appetite stimulation via central ghrelin signalling — distinct orexigenic side-effect profile.

Hexarelin 5mg

Hexarelin

Hexapeptide GH secretagogue. 99.0% purity. 5mg vial; highest GH-stimulating potency in the GHRP class; also binds CD36 and GHS-R1b conferring cardioprotective signalling in preclinical models.

Tesamorelin 10mg

Tesamorelin

GHRH analogue (trans-3-hexenoic acid modification). 99.1% purity. 10mg vial; FDA-approved mechanism for visceral adipose reduction in HIV lipodystrophy; clinical data on VAT decrease.

Tesamorelin 20mg

Tesamorelin

GHRH analogue (trans-3-hexenoic acid modification). 99.1% purity. 20mg bulk vial; FDA-approved mechanism in lipodystrophy; extended supply for visceral adipose tissue longitudinal studies.

Ipamorelin/CJC-1295 Blend 10mg

Ipamorelin 5mg + CJC-1295 No DAC 5mg pre-formulated blend. 99.0% purity. Combines GHRH-receptor activation with ghrelin-receptor agonism for synergistic GH pulse amplification.

Ipamorelin/CJC-1295 Blend 10mg v2

CJC-1295 No DAC 5mg + Ipamorelin 5mg dual-pathway blend. 99.0% purity. GHRH + GHSR co-activation without cortisol or prolactin elevation; suitable for selective GH pulse research.

Ipamorelin/Tesamorelin Blend 13mg

Ipamorelin 3mg + Tesamorelin 10mg blend. 99.0% purity. Ghrelin-receptor GH pulse trigger combined with VAT-targeting GHRH analogue; ipamorelin-light ratio for pulse + visceral fat protocols.

Ipamorelin/Tesamorelin Blend 15mg

Ipamorelin 5mg + Tesamorelin 10mg blend. 99.0% purity. Equal-intensity ghrelin/GHRH co-activation; combines selective GH pulse induction with clinically validated visceral adipose reduction pathway.

IPA/TESA Blend 15mg

Ipamorelin 5mg + Tesamorelin 10mg blend, 15mg total vial. 99.0% purity. Dual GH pathway — ghrelin-receptor pulse trigger plus GHRH-mediated visceral fat reduction in single preparation.

PEG-MGF 2mg

PEG-MGF (IGF-1Ec)

PEGylated Mechano Growth Factor, IGF-1Ec splice variant. 98.8% purity. 2mg vial; PEGylation extends circulating half-life; activates satellite cell proliferation for localised muscle repair research.

IGF-1 LR3 1mg

IGF-1 LR3

Long R3 IGF-1 analogue. 98.7% purity. 1mg vial; Arg-3 substitution reduces IGFBP binding, extending half-life ~13× vs native IGF-1; drives systemic anabolic signalling via IGF-1R.

Kisspeptin-10 5mg

Kisspeptin-10

Kisspeptin-10 hypothalamic neuropeptide. 98.9% purity. 5mg starter vial; binds KISS1R to drive GnRH pulse release, secondarily elevating LH and FSH — foundational HPG axis research tool.

Kisspeptin-10 10mg

Kisspeptin-10

Kisspeptin-10 hypothalamic neuropeptide. 98.9% purity. 10mg extended-supply vial; sustained KISS1R-mediated GnRH stimulation studies; double the supply of 5mg vial for multi-week protocols.

Gonadorelin Acetate

Gonadorelin Acetate

Synthetic GnRH decapeptide. 99.0% purity. Binds pituitary GnRH-R to trigger LH and FSH secretion; pulse vs continuous administration produces markedly different gonadotropin response profiles.

BPC-157 10mg

Body Protection Compound-157

15-amino-acid synthetic pentadecapeptide. 140+ preclinical studies; upregulates VEGFR2 and FAK-paxillin signalling for tissue repair. 99.3% purity. Standard research vial.

BPC-157 Capsules 500mcg x60

Body Protection Compound-157

BPC-157 in oral capsule form, 500mcg per cap, 60-count supply. Gut-targeted delivery; bypasses injection for gastrointestinal tract research. 99.0% purity.

BPC-157 + TB-500 Blend 20mg

BPC-157 10mg + TB-500 10mg dual-mechanism blend. VEGFR2 local repair paired with G-actin systemic cell migration. 20mg total. 99.0% purity.

BPC-157 + TB-500 Blend 10mg

BPC-157 5mg + TB-500 5mg. Starter-dose dual-mechanism blend for titration. Local VEGFR2 signalling plus systemic actin-sequestering activity. 99.0% purity.

TB-500 (Thymosin Beta-4) 10mg

Thymosin Beta-4

43-amino-acid G-actin sequestering protein. Promotes systemic cell migration, angiogenesis, and tissue remodelling. ~10-day half-life. 99.0% purity.

Thymosin Alpha-1 5mg

Thymosin Alpha-1

28-amino-acid thymic peptide. Promotes T-cell differentiation, enhances dendritic cell function, and upregulates MHC class I expression. Starter vial. 99.0% purity.

Thymosin Alpha-1 10mg

Thymosin Alpha-1

28-amino-acid thymic peptide. T-cell differentiation and cytokine modulation; Zadaxin approved in 37 countries. Full research vial. 99.0% purity.

Thymulin 10mg

Thymulin

Thymic nonapeptide requiring zinc for biological activity. Central role in T-lymphocyte differentiation and CD4+/CD8+ ratio modulation. 98.8% purity.

Thymogen 20mg

Thymogen

Glu-Trp dipeptide thymic bioregulator. Khavinson-studied compound for T-cell function, immune restoration, and cytokine balance. 98.8% purity.

LL-37 10mg

LL-37 (Cathelicidin)

Human cathelicidin-derived 37-residue antimicrobial peptide. Membrane-disrupting bactericidal action; studied for wound healing and TLR4 modulation. 98.9% purity.

KPV 5mg

KPV (Lys-Pro-Val)

Alpha-MSH C-terminal tripeptide (Lys-Pro-Val). Inhibits NF-kB nuclear translocation; studied in colitis and skin inflammation models. Starter vial. 99.0% purity.

KPV 10mg

KPV (Lys-Pro-Val)

Alpha-MSH C-terminal tripeptide (Lys-Pro-Val). NF-kB pathway inhibition studied in IBD and skin inflammation preclinical models. Full research vial. 99.0% purity.

ARA-290 10mg

ARA-290

11-amino-acid non-hematopoietic EPO analogue. Selectively binds innate repair receptor; neuroprotective and anti-inflammatory without erythropoietic effects. 98.7% purity.

VIP 5mg

Vasoactive Intestinal Peptide

28-amino-acid vasoactive intestinal peptide. Activates VPAC1/VPAC2 receptors for immunomodulatory and bronchodilatory effects. Starter vial. 98.8% purity.

VIP 10mg

Vasoactive Intestinal Peptide

28-amino-acid vasoactive intestinal peptide. VPAC1/VPAC2 agonism modulates Th1/Th2 balance; studied in autoimmune and pulmonary fibrosis models. Full vial. 98.8% purity.

SS-31 10mg

SS-31 (Elamipretide)

Elamipretide tetrapeptide. Localises to cardiolipin at inner mitochondrial membrane, suppressing ROS and restoring cristae structure. Starter vial. 98.9% purity.

SS-31 25mg

SS-31 (Elamipretide)

Elamipretide tetrapeptide, 25mg. Cardiolipin-targeted ROS suppression at inner mitochondrial membrane. Mid-range titration supply. 98.9% purity.

SS-31 50mg

SS-31 (Elamipretide)

Elamipretide tetrapeptide, 50mg. Cardiolipin-binding ROS reduction at inner mitochondrial membrane. Extended longitudinal protocol supply. 98.9% purity.

MOTS-c 10mg

MOTS-c

Mitochondria-derived peptide encoded in 12S rRNA. AMPK activation promotes metabolic flexibility and insulin sensitivity in skeletal muscle. Starter vial. 98.8% purity.

MOTS-c 20mg

MOTS-c

Mitochondria-derived AMPK-activating peptide, 20mg. Metabolic flexibility and aging-associated insulin resistance studied in Kim et al. (2021). Maintenance supply. 98.8% purity.

MOTS-c 40mg

MOTS-c

Mitochondria-derived 12S rRNA-encoded AMPK activator, 40mg. Extended longevity and metabolic homeostasis research supply. 98.8% purity.

Oxytocin 8mg

Oxytocin

Nonapeptide neurohormone, 8mg. Modulates OXTR-mediated social cognition, HPA stress-axis regulation, and enteric gut motility. Starter vial. 99.0% purity.

Oxytocin 10mg

Oxytocin

Nonapeptide neurohormone, 10mg. OXTR agonism studied in HPA axis modulation, social behaviour, and intestinal transit research. Full research vial. 99.0% purity.

GLOW Blend 50mg

GHK-Cu-anchored aesthetic peptide blend, 50mg. Copper tripeptide collagen modulation combined with complementary skin matrix-targeting sequences. 98.8% purity.

GLOW Blend 70mg

GHK-Cu-anchored aesthetic peptide blend, 70mg. Larger supply of collagen-upregulating copper tripeptide plus skin matrix peptide stack. 98.8% purity.

KLOW Blend 80mg

Multi-peptide recovery and longevity blend, 80mg. Mitochondrial, anti-senescent, and tissue-repair targets combined in a single research vial. 98.8% purity.

GHK-Cu 50mg

Copper Peptide GHK-Cu

Gly-His-Lys copper tripeptide, 50mg. Upregulates collagen I by ~70%, activates SOD and antioxidant enzymes, modulates 4,000+ genes. 99.1% purity.

GHK-Cu 100mg

Copper Peptide GHK-Cu

Gly-His-Lys copper tripeptide, 100mg. Collagen I, elastin, and antioxidant enzyme gene modulation across 4,000+ gene targets. Extended research supply. 99.1% purity.

Epitalon 10mg

Epitalon (Epithalon)

Ala-Glu-Asp-Gly tetrapeptide from Khavinson pineal research. Activates telomerase via hTERT induction; melatonin modulation across 50+ years of longitudinal data. 99.2% purity.

Epitalon 50mg

Epitalon (Epithalon)

Ala-Glu-Asp-Gly telomerase-activating tetrapeptide, 50mg. Khavinson lifespan-extension and telomere data. Bulk supply for extended longevity protocols. 99.4% purity.

NA-Epitalon 10mg

NA-Epitalon

N-acetylated, C-terminally amidated Epitalon analogue. Enhanced lipophilicity improves proteolytic stability and BBB permeability over native Epitalon. 99.0% purity.

SNAP-8 10mg

Acetyl Octapeptide-3

8-amino-acid SNARE-complex-targeting peptide. Synaptosome-level competitive inhibition; preclinical data report up to 63% reduction in wrinkle depth. 98.9% purity.

FOXO4-DRI 10mg

FOXO4-DRI

D-amino acid retro-inverso FOXO4 peptide. Disrupts FOXO4-p53 binding to selectively induce apoptosis in p21-positive senescent cells. 98.7% purity.

PNC-27 30mg

PNC-27

p53 HDM-2 binding domain peptide. Preferentially forms transmembrane pores in cancer cell membranes with selectivity over normal cells. 98.6% purity.

P21 10mg

P21

BDNF loop 2-derived peptide. Promotes hippocampal neurogenesis and synaptic plasticity in preclinical models. Distinct from p21 cell cycle protein. 98.7% purity.

NAD+ 500mg

Nicotinamide Adenine Dinucleotide (NAD+)

Nicotinamide adenine dinucleotide, 500mg. Sirtuin and PARP co-substrate; intracellular levels decline ~50% between ages 40-60. Starter repletion vial. 99.5% purity.

NAD+ 1000mg

Nicotinamide Adenine Dinucleotide (NAD+)

Nicotinamide adenine dinucleotide, 1000mg. Sirtuin co-substrate and PARP activator for DNA repair; extended NAD+ repletion research supply. 99.5% purity.

Glutathione 200mg

Glutathione (GSH)

Gamma-Glu-Cys-Gly tripeptide, 200mg. Maintains cellular GSH/GSSG redox ratio, supports Phase II detoxification and GST enzyme activity. 99.3% purity.

Glutathione 600mg

Glutathione (GSH)

Reduced glutathione 600mg. Cytosolic redox buffer for heavy metal chelation, GST co-factor activity, and NK cell function studies. Maintenance supply. 99.3% purity.

Glutathione 1500mg

Glutathione (GSH)

Reduced glutathione 1500mg. GSH/GSSG ratio maintenance, hepatic Phase II conjugation, and antioxidant enzyme regeneration. Extended protocol supply. 99.3% purity.

Methylene Blue 10mg/mL 50mL

Methylene Blue

Phenothiazine electron carrier, 10mg/mL, 50mL. Facilitates mitochondrial Complex I/III transfer; studied in neuroprotection and cognitive aging. 99.5% purity.

ACE-031 1mg

ACE-031 (ACVR2B-Fc)

ActRIIB-Fc fusion protein. Traps myostatin and activin A, relieving Smad2/3 inhibition of myogenesis. Phase II musculoskeletal data available. 98.5% purity.

Abaloparatide 3mg

Abaloparatide

PTHrP(1-34) analogue with selective RG conformation binding. FDA-approved (Tymlos); ACTIVE trial: +3.4% lumbar spine BMD at 18 months. 98.7% purity.

Bronchogen 20mg

Bronchogen (Ala-Glu-Asp-Leu)

Ala-Glu-Asp-Leu tetrapeptide Khavinson bioregulator. Tissue-specific gene regulation studied in bronchial epithelium and pulmonary function models. 98.8% purity.

Cardiogen 20mg

Cardiogen (Ala-Glu-Asp-Arg)

Ala-Glu-Asp-Arg tetrapeptide Khavinson bioregulator. Cardiac tissue-specific chromatin modulation studied in myocardial function and aging models. 98.8% purity.

Cartalax 20mg

Cartalax (Ala-Glu-Asp-Pro)

Ala-Glu-Asp-Gly tetrapeptide Khavinson bioregulator. Connective tissue gene regulation studied in cartilage and extracellular matrix models. 98.8% purity.

Chonluten 20mg

Chonluten

Gly-Glu-Pro tripeptide Khavinson bioregulator. Bronchial mucous membrane gene expression modulation; studied in respiratory epithelium models. 98.8% purity.

Cortagen 20mg

Cortagen

Ala-Glu-Asp-Pro tetrapeptide Khavinson bioregulator. Cortex tissue-specific gene regulation studied in neurological function and cortical aging models. 98.8% purity.

Crystagen 20mg

Crystagen

Lys-Glu tetrapeptide Khavinson bioregulator. Immune system-targeted gene regulation studied in lymphocyte function and immunosenescence models. 98.8% purity.

Livagen 20mg

Livagen (Lys-Glu-Asp-Ala)

Lys-Glu-Asp tetrapeptide Khavinson bioregulator. Hepatic chromatin decondensation and immune modulation studied in aging liver tissue models. 98.8% purity.

Ovagen 20mg

Ovagen

Gly-Glu-Asp tetrapeptide Khavinson bioregulator. Targets liver and gastrointestinal tissue gene expression in hepatic and GI function research. 98.8% purity.

Pancragen 20mg

Pancragen

Lys-Glu-Asp-Trp tetrapeptide Khavinson bioregulator. Pancreatic tissue gene regulation studied in insulin secretion and glycemic pathway models. 98.8% purity.

Pinealon 10mg

Pinealon (Glu-Asp-Arg)

Glu-Asp-Arg tripeptide Khavinson bioregulator, 10mg. Pineal and cortical tissue gene regulation studied in neuroprotection and circadian models. 98.8% purity.

Pinealon 20mg

Pinealon (Glu-Asp-Arg)

Glu-Asp-Arg tripeptide Khavinson bioregulator, 20mg. Extended pineal and cortical tissue gene modulation for neuroprotection research. 98.8% purity.

Prostamax 20mg

Prostamax

Lys-Glu-Asp-Pro tetrapeptide Khavinson bioregulator. Prostate tissue gene regulation studied in male glandular function and aging models. 98.8% purity.

Testagen 20mg

Testagen

Lys-Asp-Glu tetrapeptide Khavinson bioregulator. Testicular tissue chromatin modulation studied in male endocrine and androgen pathway research. 98.8% purity.

Vesilute 20mg

Vesilute

Khavinson peptide bioregulator targeting bladder epithelium. Gene-regulatory activity studied in urological tissue and urinary function models. 98.8% purity.

Vesugen 20mg

Vesugen (Lys-Glu-Asp-Trp)

Lys-Glu-Gly tetrapeptide Khavinson bioregulator. Vascular endothelial tissue regulation studied in arterial wall and endothelial function models. 98.8% purity.

Vilon 20mg

Vilon (Lys-Glu)

Lys-Glu dipeptide Khavinson bioregulator. Thymic and immune gene modulation; among earliest bioregulatory peptides in Khavinson aging trials. 98.8% purity.

Selank 10mg

Selank

Tuftsin-derived heptapeptide (TKPRPGP). GABAergic modulation and BDNF upregulation; anxiolysis studied without sedation or dependence signals. 99.0% purity.

NA-Selank Amidate 10mg

NA-Selank Amidate

N-acetyl amidated Selank analogue, 10mg. C-terminal amidation and N-acetyl group enhance proteolytic resistance and BBB penetration. 99.0% purity.

NA-Selank Amidate 30mg

NA-Selank Amidate

N-acetyl amidated Selank analogue, 30mg. Extended anxiolytic and nootropic research supply with improved BBB penetration over native Selank. 99.0% purity.

N-Acetyl Semax Amidate 30mg

N-Acetyl Semax Amidate

N-acetyl amidated ACTH(4-7) analogue. Upregulates BDNF/NGF; stabilised sequence vs. native Semax. 30mg bulk supply for cognitive protocols. 99.0% purity.

DSIP 5mg

DSIP (Delta Sleep-Inducing Peptide)

Delta sleep-inducing nonapeptide. EEG delta-wave promotion; LH/GH and corticotropin axis modulation in sleep research models. Starter vial. 99.0% purity.

DSIP 10mg

DSIP (Delta Sleep-Inducing Peptide)

Delta sleep-inducing nonapeptide, 10mg. Monnier (1977) isolation; delta-wave EEG promotion and stress hormone normalisation studied. Research vial. 99.0% purity.

DSIP 15mg

DSIP (Delta Sleep-Inducing Peptide)

Delta sleep-inducing nonapeptide, 15mg. EEG delta-wave modulation with concurrent LH/GH axis effects; extended sleep research supply. 99.0% purity.

PE-22-28 10mg

PE-22-28

TREK-1 blocking BDNF-mimetic derived from spadin scaffold. Antidepressant-like behaviour in FST models via non-serotonergic mechanism. 98.8% purity.

Adamax 10mg

Adamax

Nootropic peptide targeting TrkB and BDNF signalling cascade. Memory consolidation and neuroprotective outcomes in rodent cognitive models. 98.7% purity.

Melanotan I 10mg

Melanotan I (Afamelanotide)

Linear alpha-MSH analogue. Selective MC1R agonism drives melanocyte stimulation; FDA-approved analogue (afamelanotide) for erythropoietic protoporphyria. 99.0% purity.

Melanotan II 10mg

Melanotan II

Cyclic alpha-MSH analogue. MC1R agonism for melanogenesis; concurrent MC3R/MC4R agonism associated with appetite suppression and libido effects. 99.0% purity.

PT-141 10mg

PT-141 (Bremelanotide)

Bremelanotide MC1R/MC3R/MC4R agonist. FDA-approved (Vyleesi) for HSDD. CNS-based mechanism distinct from PDE5 inhibition. 99.0% purity.

RU-58841 50mg x30mL

RU-58841

Non-systemic topical AR antagonist, 50mg/30mL. Follicle-level DHT blockade without measurable systemic anti-androgen activity in alopecia models. 98.8% purity.

RU-58841 50mg x60mL

RU-58841

Non-systemic topical AR antagonist, 50mg/60mL. Doubled volume vs. 30mL format; extended supply for androgenic alopecia research protocols. 98.8% purity.

5-Amino-1MQ 50mg

5-Amino-1MQ

NNMT inhibitor. 98.9% purity. 50mg injectable vial; blocks nicotinamide N-methyltransferase to raise intracellular NAD+ and reduce triglyceride accumulation in differentiated adipocytes.

5-Amino-1MQ 5mg

5-Amino-1MQ

NNMT inhibitor. 98.9% purity. 5mg micro-dose starter vial; entry-level supply for NNMT inhibition dose-response studies targeting NAD+ elevation and adipocyte lipid reduction.

5-Amino-1MQ 50mg x60 Capsules

5-Amino-1MQ

NNMT inhibitor, oral capsule format. 98.9% purity. 50mg × 60 capsules; blocks nicotinamide N-methyltransferase to increase NAD+ availability and attenuate adipocyte lipid accumulation.

Bacteriostatic Water 30mL

0.9% benzyl alcohol in sterile water. Bacteriostatic agent inhibits microbial growth enabling multi-draw use. Standard diluent for lyophilised peptide reconstitution.

Bacteriostatic Water USP 30mL

USP-grade 0.9% benzyl alcohol bacteriostatic water. Meets Pharmacopeia sterility and endotoxin specifications. 30mL multi-use vial for lyophilised peptide reconstitution.